Vyriad, a gene therapy company based in Rochester, has raised $85 million to support its new VV-169 cancer treatment which ...

The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...

In this week's "It's Debatable" segment, Rick Rosen and Charles Moster debate on the question: Should ethical/legal restrictions on human testing be lifted to expedite the development of new ...

For the first time, a federal health agency’s cervical cancer screening guidance includes an option for women to collect ...

Researchers with UNC School of Medicine, Gillings School of Global Health, and Lineberger Comprehensive Cancer Center ...